What the results of Wegovy’s longest clinical trial yet show about ...
May 13, 2024 · CNN — New analyses of the longest clinical trial yet of the weight-loss drug Wegovy are shedding light on how quickly it helps people lose weight, how long they sustain that weight loss and how...
FDA Approves First Treatment to Reduce Risk of Serious Heart …
Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults...
Weight-loss drug Wegovy produces ‘largest benefit ever seen’ for ...
Aug 25, 2023 · A study found that a 2.4-milligram weekly dose of semaglutide, sold as Wegovy for weight loss, led to an improvement of 17 points on a 100-point scale that’s used to assess symptoms of a...
FDA Approves New Drug Treatment for Chronic Weight …
FDA approves Wegovy (semaglutide) injection for chronic weight management in adults with obesity or overweight with at least one weight-related condition.
Results of Wegovy's longest clinical trial on weight loss ... - CTV News
May 14, 2024 · The analysis showed an average weight loss of just over 10 per cent for people who used semaglutide, the active ingredient in Wegovy, compared with 1.5 per cent for study participants who got a...
News details - Novo Nordisk
Mar 8, 2024 · Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity. Wegovy® (semaglutide) injection 2.4 mg is the first-and-only medicine indicated for both reduction of the risk of major adverse cardiovascular events (MACE) such as death, heart attack, or stroke and for long-term ...
The weight-loss drug Wegovy lowered heart attack risk in a large …
Nov 15, 2023 · Among 17,000 adults, those on semaglutide were less likely to experience nonfatal heart attacks and strokes or death due to cardiovascular disease.
Novo Nordisk receives FDA approval for Wegovy™ to treat …
PLAINSBORO, N.J., June 4, 2021 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the new drug application (NDA) for Wegovy ™ (semaglutide)...
Obesity drug Wegovy cut risk of serious heart problems by 20%: …
Nov 11, 2023 · A new large study finds that the popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in certain patients. The international trial showed the weekly injections prevented heart attacks, strokes and heart-related deaths.
Weight-loss drug lowers cardiovascular disease risk in new trial of ...
Aug 24, 2023 · Novo Nordisk released results from its SELECT trial on 8 August 2023 showing that patients receiving the GLP-1 analog semaglutide (Wegovy) had a 20% reduction in cardiovascular events compared...
- Some results have been removed